251 related articles for article (PubMed ID: 21155183)
1. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y
J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
Zhan P; Wang J; Lv XJ; Wang Q; Qiu LX; Lin XQ; Yu LK; Song Y
J Thorac Oncol; 2009 Sep; 4(9):1094-103. PubMed ID: 19687765
[TBL] [Abstract][Full Text] [Related]
3. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
6. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
[TBL] [Abstract][Full Text] [Related]
7. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
[TBL] [Abstract][Full Text] [Related]
11. Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.
Ko YS; Kim NY; Pyo JS
Int J Biol Markers; 2018 Jan; 33(1):49-54. PubMed ID: 28478639
[TBL] [Abstract][Full Text] [Related]
12. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
Kuyama S; Hotta K; Tabata M; Segawa Y; Fujiwara Y; Takigawa N; Kiura K; Ueoka H; Eguchi K; Tanimoto M
J Thorac Oncol; 2008 May; 3(5):477-82. PubMed ID: 18448999
[TBL] [Abstract][Full Text] [Related]
13. Investigation of HER2 overexpression in non-small cell lung cancer.
Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
[TBL] [Abstract][Full Text] [Related]
14. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.
Onn A; Choe DH; Herbst RS; Correa AM; Munden RF; Truong MT; Vaporciyan AA; Isobe T; Gilcrease MZ; Marom EM
Radiology; 2005 Oct; 237(1):342-7. PubMed ID: 16183941
[TBL] [Abstract][Full Text] [Related]
15. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
[TBL] [Abstract][Full Text] [Related]
16. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
Wang Y; He L; Cheng Y
Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
[TBL] [Abstract][Full Text] [Related]
17. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
Mar N; Vredenburgh JJ
Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
[TBL] [Abstract][Full Text] [Related]
18. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
19. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.
Wang Y; Gao W; Xu J; Chen X; Yang Y; Zhu Y; Yin Y; Guo R; Liu P; Shu Y; Liu L
Biomed Res Int; 2015; 2015():763080. PubMed ID: 26788508
[TBL] [Abstract][Full Text] [Related]
20. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]